Suppr超能文献

The angiotensin II receptor antagonist losartan: a new advance in the treatment of hypertension.

作者信息

Lacourcière Y

机构信息

Department of Physiology and Medicine, Université de Montréal, Québec.

出版信息

Can J Cardiol. 1995 Aug;11 Suppl F:45F-48F.

PMID:7664218
Abstract

Losartan is the first of a new class of antihypertensive agents called 'angiotensin II antagonists'. It selectively and completely blocks the binding of angiotensin II at the angiotensin type 1 receptor-a unique mechanism of action different from all the other classes of antihypertensive agents. Losartan is as effective as other commonly used antihypertensive agents, but it permits convenient dosing and is better tolerated. On the strength of current data on its safety and efficacy, losartan should be considered a valuable option for many hypertension patients in whom angiotensin-converting enzyme inhibitors or calcium antagonists would be used. Although the administration of losartan produces beneficial effects and may be cost effective, long term data regarding morbidity and mortality in hypertension are needed.

摘要

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验